HER2-negative breast tumors include cancers that don't respond to drugs that target the HER2 protein, the American Society of Clinical Oncology (ASCO) explained Tuesday in a news release.
"In releasing this guideline, our aim is to improve both the length and quality of patients' lives," Dr. Ann Partridge, co-chair of the expert panel that developed the guidelines, said in the statement. "Although no clear chemotherapy winner emerged -- the guideline will help doctors and patients choose the best therapy based on what treatment would be most tolerable and convenient for the patient."
The guidelines are published in the Sept. 2 issue of the Journal of Clinical Oncology.
No comments:
Post a Comment